Amylyx Pharmaceuticals (AMLX) Research & Development (2021 - 2026)

Amylyx Pharmaceuticals' Research & Development history runs 6 years deep, the most recent figure standing at $27.6 million for Q1 2026.

• On a quarterly basis, Research & Development rose 24.82% year-over-year to $27.6 million in Q1 2026; TTM through Mar 2026 was $95.9 million, a 7.03% increase from a year earlier, with the FY2025 full-year figure at $90.4 million, down 13.14% from the prior year.
• Research & Development grew to $27.6 million in Q1 2026 per AMLX's latest filing, from $21.2 million in the prior quarter.
• Across five years, Research & Development topped out at $44.9 million in Q4 2023 and bottomed at $19.9 million in Q3 2025.
• The 5-year median for Research & Development is $24.2 million (2023), against an average of $26.1 million.
• Across the five-year window, Research & Development jumped 212.7% in 2022 and plunged 49.03% in 2024, its largest moves.
• Year by year, Research & Development stood at $22.8 million in 2022, then soared by 96.88% to $44.9 million in 2023, then tumbled by 49.03% to $22.9 million in 2024, then decreased by 7.33% to $21.2 million in 2025, then surged by 30.16% to $27.6 million in 2026.
• Per Business Quant, the three latest AMLX Research & Development figures stand at $27.6 million (Q1 2026), $21.2 million (Q4 2025), and $19.9 million (Q3 2025).